SCHEMBL38500

SCHEMBL38500

[c]1ccccc1-c1cccnc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 11/20 0.54
CYP3A4 P08684 4/20 0.54
ALDH1A1 P00352 3/20 0.54
CYP1A2 P05177 1/20 0.54
KDM4E B2RXH2 2/20 0.47
HPGD P15428 2/20 0.47
HSD17B10 Q99714 2/20 0.47
TP53 P04637 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
LMNA P02545 1/20 0.47
MAPT P10636 1/20 0.47
ALOX15 P16050 1/20 0.47
HTT P42858 1/20 0.47
CYP2B6 P20813 4/20 0.44
CYP2C9 P11712 3/20 0.44
CYP2C19 P33261 2/20 0.44
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
CYP19A1 P11511 3/20 0.43
CYP11B1 P15538 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9958537 0.91 CYP2A6 (0.54) CYP2A6CYP3A4ALDH1A1CYP1A2KDM4E
SCHEMBL9958003 0.88 CYP2A6 (0.50) CYP2A6CYP3A4ALDH1A1CYP1A2KDM4E
SCHEMBL15511154 0.88 CYP2A6 (0.50) CYP2A6CYP3A4ALDH1A1CYP1A2KDM4E
SCHEMBL9958153 0.85 CYP2A6 (0.47) CYP2A6CYP3A4ALDH1A1CYP1A2KDM4E
SCHEMBL10965014 0.82 CYP2A6 (0.56) CYP2A6CYP3A4ALDH1A1CYP1A2KDM4E
SCHEMBL722168 0.79 ATM (0.54) CYP2A6CYP3A4ALDH1A1CYP1A2KDM4E
SCHEMBL9958676 0.78 CYP19A1 (0.50) CYP2A6CYP3A4ALDH1A1CYP1A2KDM4E
SCHEMBL28917460 0.77 MKNK1 (0.45) CYP2A6CYP19A1CYP11B1CYP11B2MKNK1
SCHEMBL38689 0.77 NOTUM (0.48) CYP3A4ALDH1A1CYP1A2KDM4EHSD17B10
SCHEMBL10013004 0.76 HDAC4 (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 338 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210292281-A1 PYRAZOLE AND IMIDAZOLE COMPOUNDS FOR INHIBITION OF IL-17 AND RORGAMMA REATA PHARMACEUTICALS, INC. (US) 2021-09-23 US claimed
EP-3807265-A1 PYRAZOLE AND IMIDAZOLE COMPOUNDS FOR INHIBITION OF IL-17 AND RORGAMMA Reata Pharmaceuticals, Inc. (US) 2021-04-21 EP claimed
CN-108493343-B Perovskite film, preparation method thereof and application of film in photoelectric device 清华大学 2020-04-24 CN claimed
CN-107946484-B A kind of white light organic electroluminescent device and preparation method thereof 吉林大学 2019-07-26 CN claimed
CN-109326736-A A kind of coplanar electrode type organic electroluminescence device of adjustable color and its application 吉林大学 2019-02-12 CN claimed
CN-109134520-A A kind of hot activation delay material and the organic photoelectric device comprising it 上海天马有机发光显示技术有限公司 2019-01-04 CN claimed
CN-107946484-A A kind of white light organic electroluminescent device and preparation method thereof 吉林大学 2018-04-20 CN claimed
CN-106414429-A Pyrazole compounds and their use as T-type calcium channel blockers 埃科特莱茵药品有限公司 2017-02-15 CN claimed
US-20150299163-A1 COMPOUNDS FOR USE IN THE TREATMENT OF PARASITIC DISEASES IRBM - SCIENCE PARK S.P.A. (IT) 2015-10-22 US claimed
EP-2914589-A1 COMPOUNDS FOR USE IN THE TREATMENT OF PARASITIC DISEASES IRBM - Science Park S.p.A. (IT) 2015-09-09 EP claimed
WO-2003024923-A1 SULFONAMIDE COMPOUNDS AS PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2003-03-27 WO claimed
US-6432993-B1 BENZIMIDAZOLE OR IMIDAZO(4,5-B)PYRIDINE DERIVATES; IMMUNOMODULATORS; ALDOSE REDUCTASE AND LIPOXYGENASE INHIBITORS; DIABETES; PREVENTS LIPID PEROXIDATION; ANTILIPEMIC, HYPOTENSIVE AGENTS SANKYO COMPANY, LIMITED (JP) 2002-08-13 US claimed
WO-2002032879-A1 DIHYDROPYRIMIDINE DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS NAEJA PHARMACEUTICAL INC. (CA) 2002-04-25 WO claimed
US-6291460-B1 TREATMENT OF ANXIETY; TREATMENT AND/OR PREVENTION OF CONVULSIONS MERCK SHARP & DOHME LIMITED (GB) 2001-09-18 US claimed
EP-1056748-A1 TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LTD. (GB) 2000-12-06 EP claimed
EP-1022272-A1 SUBSTITUTED FUSED HETEROCYCLIC COMPOUNDS Sankyo Company Limited (JP) 2000-07-26 EP claimed
WO-1999037647-A1 TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LIMITED (GB) 1999-07-29 WO claimed
JP-H09502702-A 1997-03-18 JP claimed
EP-0706514-A1 COMPOUNDS AND METHODS FOR INHIBITION OF HIV AND RELATED VIRUSES MEDIVIR AB (SE) 1996-04-17 EP claimed
WO-1995006034-A1 COMPOUNDS AND METHODS FOR INHIBITION OF HIV AND RELATED VIRUSES MEDIVIR AB (SE) 1995-03-02 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150299163-A1 COMPOUNDS FOR USE IN THE TREATMENT OF PARASITIC DISEASES HDAC3, HDAC5, HDAC1 CYP2A6 3823/4885CYP3A4 3531/4885ALDH1A1 1001/4885
US-20210292281-A1 PYRAZOLE AND IMIDAZOLE COMPOUNDS FOR INHIBITION OF IL-17 AND RORGAMMA RORC, RORB, RORA CYP2A6 764/4885CYP3A4 270/4885ALDH1A1 672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.